We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expedited Safety Reporting: How to Submit More Meaningful Data
Expedited Safety Reporting: How to Submit More Meaningful Data
January 16, 2013
An end-of-year FDA final guidance clarifies expedited safety reporting requirements for drugs under an investigational new drug (IND) application, as the agency works to cut down on unnecessary adverse experience reports.